WHAT IS CLAIMED IS:

1. Nutraceutical or pharmaceutical compositions rich in unsaturated fatty acids, characterized in that they contain free or combined α-linolenic acid at a concentration ranging from 70 to 90% of the global weight, admixed with fatty acids having five and/or six double-bonds, in the form of capsules, granules, powder on a powdery carrier or of drinkable emulsions.

5

10

- 2. Nutraceutical or pharmaceutical compositions according to claim 1, in which the α -linolenic acid is present as the free acid, an α -linolenic acid salt or an α -linolenic acid glyceride.
- 3. Nutraceutical or pharmaceutical compositions according to claim 1 or 2, in which α -linolenic acid is present as an adsorbate in a cellulose derivative or in a cyclodextrine.
- 4. Nutraceutical or pharmaceutical compositions according to any of the preceding claims, in which the fatty acid with five double-bonds is eicosapentaenoic acid.
- 15 5. Nutraceutical or pharmaceutical compositions according to any of claims 1 to 3, in which the fatty acid with six double-bonds is docosahexaenoic acid.
 - 6. Nutraceutical or pharmaceutical compositions according to claim 4, in which the fatty acid with five double-bonds is present as a fish oil, selected among halibut oil, cod liver oil, haddock oil, tuna oil, sardine oil and shark oil.
- 7. Nutraceutical or pharmaceutical compositions according to claim 5, in which the six double-bond fatty acid is present as fish oil, selected among tuna oil and sardine oil.
 - 8. Nutraceutical or pharmaceutical compositions according to any of the preceding claims, in which α -linolenic acid is present as an oil rich or concentrated in α -linolenic acid.
- 9. Nutraceutical or pharmaceutical compositions according to any of the preceding claims, in which α-linolenic acid is present as kiwi seed oil.
 - 10. Nutraceutical or pharmaceutical compositions according to any of the preceding claims, in which eicosapentaenoic acid constitutes from 10 to 20% of the global weight.
- 30 11. Nutraceutical or pharmaceutical compositions according to any of the preceding claims, in which docosahexaenoic acid constitutes from 25 to 35% of the global weight.
 - 12. Nutraceutical or pharmaceutical compositions according to any of the preceding claims, which also contains some γ-linolenic acid.
- 13. Nutraceutical or pharmaceutical compositions according to any of claims 1 to 12, containing from 800 to 1.000 mg of α-linolenic acid, from 80 to 120 mg of eicosapentaenoic acid and from 250 to 300 mg of docosahexaenoic acid, in the form of capsules, granules, powder on a powdery carrier or drinkable emulsions.
- 14. Nutraceutical or pharmaceutical compositions according to any of the preceding claims, in which the excipient or vehicle is a neutral oil, stable towards rancidity, selected among almond oil, peanut oil, cotton seed oil, corn oil, water mixed with polysorbate or a mix water/ethanol mixed with polyethyleneglycol stearate.

- 15. Nutraceutical or pharmaceutical compositions according to any of the preceding claims, in the form of capsules, granules, powder on a powdery carrier or drinkable emulsions.
- 16. Nutraceutical or pharmaceutical compositions according to any of the preceding claims, characterized in that they contain about 900 mg of α -linolenic acid, about 100 mg of eicosapentaenoic acid, about 270 mg of docosahexaenoic acid and about 115 mg of γ -linolenic acid, dispersed in an oil stable towards rancidity.